We estimated the effectiveness of pertussis vaccination in reducing the clinical severity of breakthrough disease among vaccinated individuals from a comprehensive follow-up study of a community of 30,000 residents of Niakhar, Senegal, in 1993. A physician examined all children with potential pertussis (cough of 17 days' duration). Samples were collected from 97% of these children for culture or serologic testing as part of the active surveillance for a pertussis vaccine trial. Cases of pertussis were defined by confirmation through culture or serologic testing or by a history of contact with a person with culture-confirmed pertussis. Among children with confirmed cases, severity of illness was assessed according to a scale that combined clinical signs and symptoms. The efficacy of the vaccine in reducing disease severity was 48% (95% confidence interval, 39%-55%) among children vaccinated with 3 doses of whole-cell (67%) or acellular (32%) vaccine. Primary cases were more severe than secondary cases in residential compounds. Pertussis vaccination is effective in reducing the severity of illness.
found no difference [11] . Usually individual symptoms are studied separately. However, the multitude of pertussis symptoms suggests that creation of a scale to assess the global severity of a pertussis illness, together with a definition for pertussis infection, is required.
More accurate evaluation of the effect of pertussis vaccine on the clinical severity of disease would improve our understanding of the complete spectrum of the effects of pertussis vaccination. In this article, we propose a scale to assess the global clinical severity of a pertussis case. We then propose a method of estimating the efficacy of vaccine in reducing the clinical severity of illness, with the condition that the case of pertussis has been confirmed by culture or serologic testing [12] .
METHODS

Setting and population.
The Niakhar study area is located 150 km southeast of Dakar, Senegal, and includes 30 villages. Extended families reside in compounds. In January 1993, there were 26,306 residents living in 1800 compounds [13] . Since March 1983, all residents have been under longitudinal observation, based on annual or, since 1987, weekly visits to compounds [14] . Pertussis vaccine studies were conducted in this area in the 1990s, in accordance with the Helsinki Declaration [15, 16] . As described elsewhere [15, 17] , pertussis was endemic, with epidemics every 3-4 years, and 1993 was a pertussis epidemic year. The present analysis was restricted to children ! [15, 18] . As a result, by 1993, the population vaccine coverage had increased steadily, to 77% and 19% among children !5 and 5-14 years of age, respectively [17] . All vaccine doses were documented, and extensive checks were performed [15, 17] .
Pertussis surveillance. Active surveillance of pertussis was conducted in children !15 years of age. Trained, supervised field workers visited every compound weekly. They reported cases in children !15 years old who had potential pertussis (cough of 17 days's duration) weekly to experienced physicians who assessed each illness. Unless another disease, such tuberculosis or malaria, was definitively diagnosed, the physician visited every compound in which such a child was present weekly to ascertain whether any further cases had developed, until every affected child in the compound had stopped coughing. Older residents were included in the surveillance only if they developed potential cases. The physician was blinded to the vaccination status (vaccinated vs. unvaccinated and AC vs. WC) of the children. In addition, the physician collected laboratory samples from all consenting potential individuals. Nasopharyngeal aspirates were drawn for isolation of Bordetella pertussis or Bordetella parapertussis and for detection of B. pertussis DNA via PCR. Blood samples (acute-and convalescentphase serum samples) were obtained for measurement of IgG titers to PT or FHA by ELISA [15, 19] . Erythromycin prophylaxis was administered to all infants !6 months of age who were living in compounds in which individuals with potential pertussis were present.
Definitions. Confirmation of pertussis infection was based on the presence of at least 1 of 3 laboratory criteria: (1) isolation of B. pertussis from a nasopharyngeal aspirate ("culture positive"), (2) significant increase or decrease in PT or FHA antibodies (100% change between convalescent-and acute-phase serum samples; "serology positive") [19] , and (3) signs and symptoms of disease in an individual who lived in the same compound as a child who had onset of culture-positive disease within 28 days.
Severity of illness was assessed according to the scale shown in table 1. "Severe disease" was defined by a score greater than a particular threshold value. The main outcome measure was defined using the overall severity median score for the population. In this study, it was 6. The scale includes clinical signs and symptoms recorded by physicians during weekly visits. Death was not included in the scale, because only 1 death attributed to pertussis occurred during the study period, in an unvaccinated 2-month-old infant [17] .
"Primary cases" were those in which the date of onset was within 6 days of the onset of the first case in the compound (i.e., the home or residential unit). All cases that occurred у7 days after the first case were considered to be "secondary cases." Data analysis. Vaccine efficacy in slowing disease progression (VEp) [12] , here, in reducing severity, was a measure of the decreased severity of breakthrough disease compared with disease in unvaccinated individuals. It was measured by subtracting the relative risk of severe disease in vaccinated children, compared with unvaccinated children, who had confirmed cases of pertussis from 1: vaccinated VEp p 1 Ϫ [(severe cases/all vaccinated cases)/(severe unvaccinated cases/all unvaccinated cases)]. Sex, age, and type of case (primary or secondary) were included in a multivariate analysis in which logistic regression was used. Significant factors were subsequently retained in the analysis to give adjusted estimates of vaccine efficacy, and the regression coefficients were transformed back to the relative risk scale [20] . The bootstrap method was used to compute 95% CIs for VEp [21] .
Vaccine efficacy in reducing susceptibility (VEs) was the usual Culture only 115 (14) 46 (19) 69 (12) Serologic testing and culture for a contact 196 (23) 37 (15) 159 (27) Serologic testing only 192 (23) 49 (20) 143 (24) Culture for a contact only 177 (21) 54 (22) 123 (21) measure of the protective effect of vaccination based on the number of events per child-years at risk. It was measured by subtracting the incidence rate ratio for all confirmed cases or for cases with severe disease from 1: or only VEs p 1 Ϫ [(all severe vaccinated cases/child-years at risk among all vaccinated children)/(all or only severe unvaccinated cases/child-years at risk among all unvaccinated children)]. Child-years at risk was computed for the calendar year 1993 among susceptible children between 6 months and 8 years of age (i.e., children with no recorded history of pertussis). To be consistent, only children with no history of pertussis were considered. In computing 95% CIs for VEs, the log normality of the relative risks was assumed [22] .
To assess potential bias in the selection of confirmed cases, we examined clinical illnesses among children with potential cases of pertussis whose culture and serologic test results were negative and among children for whom no laboratory samples were collected. We also looked at the distribution of positive laboratory test results among vaccinated and unvaccinated children. The statistical test of differences among dichotomous variables was either Pearson's x 2 test or Fisher's exact test, as appropriate; for continuous variables, the Wilcoxon rank-sum test was applied. All P values are 2-sided. The analysis was done using SAS, version 8.2 for Unix (SAS Institute).
RESULTS
Population selection.
In 1993, 2123 individuals with potential cases of pertussis (cough of 17 days' duration) were identified in 518 of 1800 residential compounds. Of these, 2080 (98%) were children !15 years of age. The majority of the children, 1657 (78%) of 2123, were either unvaccinated ( ) or completely vaccinated with 3 doses of a pertussis n p 813 vaccine ( ). In this group of 1657, all of the 85 children n p 844 who were !6 months of age and almost all ( ) of the n p 378 382 children who were у9 years of age were unvaccinated. Both of these groups of children were excluded, because no comparison of the severity of illness between unvaccinated and vaccinated cases could be performed. Thus, 1190 (72%) of 1657 children who were 6 months to 8 years of age were included in the analysis. These children represented 75% (1190 of 1584) of the potential cases in that age group. Three hundred fifty (29%) of these 1190 children were unvaccinated, and 840 (71%) had received 3 doses of a pertussis vaccine; 568 (68%) of those 840 received a WC vaccine, and 261 (31%) received an AC vaccine. Only 11 children (1%) had received doses of both vaccines alternately.
Laboratory confirmation. Among the 1190 children with potential cases of pertussis, information fulfilling 1 of the criteria for laboratory confirmation criterion was available for 98%: at least 1 test (culture or serologic test) was done for 1156 children, and culture was done for home contacts of 9 children who were not tested themselves. Thus, only 25 children had cases that were not confirmed by laboratory findings (19 Among children with confirmed cases, 123 (51%) of the 243 who were unvaccinated were girls, compared with 315 (53%) of the 594 who had been vaccinated. The median age was 6.5 years (IQR, 4.4-7.8 years) in the unvaccinated, laboratoryconfirmed group and 3.6 years (IQR, 2.1-5.0 years) in the vaccinated, laboratory-confirmed group. Eighty-four unvaccinated children (35%) and 141 vaccinated children (24%) with confirmed pertussis had primary cases. Among all 837 children with confirmed cases, only 6% had a previous history of pertussis (8% of unvaccinated and 5% of vaccinated children). Among healthy children in the same age group, 22% had a previous history of pertussis (40% of unvaccinated children and 15% of vaccinated children).
Reduction in severity. The characteristics of clinical illness in 834 children with 837 cases of confirmed pertussis are pre- sented in table 3. The overall median total score for illness severity was 6. On the basis of this threshold value of 6, 61% of unvaccinated children were considered to have severe disease, compared with 32% of vaccinated children. Thus, the estimated VEp was 48% (95% CI, 39%-55%). Unvaccinated children were twice as likely as vaccinated children to have severe disease. To examine the sensitivity of the results to the choice of the threshold value, we estimated VEp using values from 1 to 114 (table 4) . The estimated VEp varied from 11% to 83%, and in each case the lower limit of the 95% CI was 10. Thus, the significant effect of vaccination on preventing severe clinical cases was robust to the choice of threshold value for severity. Duration of illness was higher among children with severe disease than among those with mild disease (median duration, ). Thus, 90% of the children who had P ! .0001 received the AC vaccine had been vaccinated within 3 years, compared with only 32% of those who had received the WC vaccine. The proportion of children with severe cases in each group was similar (17% for WC vaccine vs. 25% for AC vaccine among children with cases that occurred !3 years after vaccination and 43% for WC vaccine vs. 44% for AC vaccine among children with cases that occurred у3 years after vaccination).
Secondary results. The VEs, which was calculated on the basis of child-years at risk, was 64% (95% CI, 55%-71%) for children with severe disease (using a threshold value of 6) and 29% (95% CI, 19%-39%) among all children with confirmed cases. Table 5 presents the characteristics of clinical illnesses in the 25 children (of 1190 children included in the study) who were not tested and in the 152 children (of 813 children for whom tests were done) who had negative results of all laboratory tests done. No statistically significant difference in severity of illness was found between unvaccinated and vaccinated children with negative results of testing. The estimated VEp was 39% (95% CI, Ϫ26% to 70%) among children with potential but unconfirmed cases of pertussis. In the group of children from whom no laboratory samples were obtained, illnesses appeared to be more severe among unvaccinated children than among vaccinated children, but the number of children in this group was small. Primary cases were more severe than secondary cases, regardless of the vaccination status of the child. Among unvaccinated children, 63 (75%) of 84 primary cases were found to be severe, compared with 86 (54%) of 159 secondary cases ( ). Likewise, among vaccinated children with break-P p .002 through cases, 62 (44%) of 141 primary cases were severe, compared with 128 (28%) of 453 secondary cases ( ). P ! .0005 Overall, culture results were positive more often for children with severe disease (41%) than for children with mild disease (27%) ( ; 50% vs. 31%, respectively, among unvacci-P ! .0001 nated and 34% vs. 26% among vaccinated children).
In a multivariate analysis, sex was not found to have any effect on the relative risk of severe disease or the corresponding VEp, whereas the type of case (primary or secondary) and the age of the child did. Age had an effect only in the vaccinated group. The interpretation of both VEp and VEs adjusted for age was hindered as a result of this age-vaccination status interaction. When children were separated into 2 age groups, !4 and у4 years, a significant interaction was found in the older group only ( ). Time since vaccination was then intro-P p .01 duced in the model, instead of age. The adjusted VEp estimates were 65% (95% CI, 56%-73%) for children vaccinated within !3 years of the onset of illness and 30% (95% CI, 18%-41%) for those vaccinated у3 years before the onset of illness. When the analysis was adjusted both for time since vaccination and for type of case, the VEp estimates for secondary cases were similar to those given above, but the VEp estimates for primary cases were lower (55% [95% CI, 45%-65%] and 24% [95% CI, 13%-34%], respectively).
DISCUSSION
These results indicate that pertussis vaccination substantially decreases the severity of breakthrough disease in children who receive 3 doses of vaccine, compared with that in unvaccinated children. The majority of the vaccinated children who devel-oped pertussis experienced mild disease, regardless of whether they had previously received a WC or an AC vaccine. Protection against severe disease was greater in recently vaccinated children than in children who had been vaccinated у3 years before the onset of illness. Our finding that immunization moderates the severity of the clinical manifestations is consistent with other reports [2, [4] [5] [6] [7] [8] [9] [10] . Laboratory samples were not obtained from asymptomatic children, and therefore we could not estimate the efficacy of the vaccine in preventing infection. We found that duration of illness was associated with severity, regardless of vaccination status. Our finding of more-severe illness in children with primary cases than in children with secondary cases suggests that a relationship exists between intensity of exposure and severity of disease (as has been suggested elsewhere [6, 23] ), if the type of case is considered to be a rough surrogate for levels of intensity of exposure.
Two aspects of our efficacy estimates differ from most others used to measure the efficacy of pertussis vaccination. First, we developed a global measure of severity, as has been done for other infectious diseases [24, 25] . Usually, when the clinical severity of pertussis disease in vaccinated and unvaccinated groups is compared, each symptom is considered individually [4, 5, 7] . Second, we studied the effect of vaccination on clinical severity (VEp) in symptomatic, infected children only. Although protective efficacy often is estimated, in terms of VEs, using a variety of case definitions that correspond to differing levels of severity [7, 15, [26] [27] [28] , the interpretation of these estimates has been different from ours. The denominator in those analyses is total child-years at risk, as in our estimates of VEs, not children with symptomatic disease and confirmed infection, as in our estimates of VEp. Chang et al. [29] suggest an efficacy measure that is based on the net burden of illness per subject and that takes both incidence and clinical severity into account. However, their measure does not condition on experiencing a confirmed episode of disease, as does ours. This is an observational study and is therefore susceptible to biases, mainly selection bias, at 2 levels: in the ascertainment of cases of pertussis or in laboratory confirmation of cases. Here, active surveillance with a low threshold for case detection (cough of 17 days' duration) probably allowed us to achieve good ascertainment of cases in vaccinated and in unvaccinated children. Nearly all children had at least 1 laboratory test done, which would also minimize selection bias in biological sampling. Slightly fewer serologic tests were performed among unvaccinated than among vaccinated children. However, rates of isolation of Bordetella were higher among unvaccinated children than among vaccinated children with breakthrough cases. Thus, the proportion of cases confirmed only indirectly, by positive results of culture of a sample from a contact, were similar in both groups. This probably indicates that confirmation rates did not differ among groups when both culture and serologic test results are considered. However, the rate of confirmation of pertussis infection might be lower in the vaccinated group. Thus, either the number of severe cases or the total number of cases should be higher than measured. If only the first number is higher among vaccinated children, then VEp would go up. In this case, our estimate of VEp is conservative. If both numbers are higher and to an equal degree, VEp does not change. If, although this is unlikely, more-severe cases were confirmed less often, our estimate is an overestimate. Selection biases are more likely to occur in studies that assess severity among hospitalized children or those who receive care at a clinic or a practitioner's office.
In summary, we studied the efficacy of pertussis vaccination, as it is used in actual practice in many developing countries (a primary series of 3 doses administered in infancy, with no subsequent booster dose), in reducing disease severity. We found that vaccination was effective in reducing the severity of breakthrough illness.
